PARP-Inhibitor Olaparib in the Treatment of Ovarian Clear Cell Cancer: Predictors of Sensitivity and Resistance

被引：0
|
作者：
Dedes, K. J.
Wilkerson, P.
Wetterskog, D.
Lambros, M. B.
Natrajan, R.
Tan, D. S.
Campion-Flora, A.
Rodrigues, D. N.
Gauthier, A.
Daley, F.
Lord, C. J.
Kaye, S. B.
Ashworth, A.
Reis-Filho, J. S.
机构：
[1] Inst Canc Res, London SW3 6JB, England
[2] Royal Marsden NHS Fdn Trust, London, England
[3] Inst Curie, Paris, France
来源：
MODERN PATHOLOGY | 2012年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1113
引用
收藏
页码：265A / 265A
页数：1
相关论文
共 50 条
  • [21] The potencial role of a PARP-inhibitor in the myocardial stem cell regeneration
    Magyar, K.
    Takacs, I.
    Bruszt, K.
    Balogh, A.
    Hideg, K.
    Seress, L.
    Sumegi, B.
    Halmosi, R.
    Toth, K.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 : 433 - 434
  • [22] Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer
    Veneziani, Ana C.
    Scott, Clare
    Wakefield, Matthew J.
    Tinker, Anna V.
    Lheureux, Stephanie
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [23] PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
    D'Andrea, Alan
    [J]. ONCOLOGIST, 2017, 22 : S1 - S1
  • [24] Diverse mechanisms of PARP inhibitor resistance in ovarian cancer
    Wakefield, Matthew John
    Nesic, Ksenija
    Kondrashova, Olga
    Scott, Clare L.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2019, 1872 (02):
  • [25] Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
    Oplustilova, Lenka
    Wolanin, Kamila
    Mistrik, Martin
    Korinkova, Gabriela
    Simkova, Dana
    Bouchal, Jan
    Lenobel, Rene
    Bartkova, Jirina
    Lau, Alan
    O'Connor, Mark J.
    Lukas, Jiri
    Bartek, Jiri
    [J]. CELL CYCLE, 2012, 11 (20) : 3837 - 3850
  • [26] PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER
    Matheson, E.
    Salehan, M.
    Mukhopadhyay, A.
    Curtin, N. J.
    Drew, Y.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 673 - 673
  • [27] Novel PARP-inhibitor combinations to treat breast cancer.
    Hu, Hai
    Taveira, Mateus de Oliveira
    Theodorou, Evangelos
    Sonzongni, Olmo
    Juvekar, Ashish
    Cantley, Lewis
    Wulf, Gerburg
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 16 - 17
  • [28] The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
    Luis Ordonez, Jose
    Teresa Amaral, Ana
    Carcaboso, Angel M.
    Herrero-Martin, David
    del Carmen Garcia-Macias, Maria
    Sevillano, Vicky
    Alonso, Diego
    Pascual-Pasto, Guillem
    San-Segundo, Laura
    Vila-Ubach, Monica
    Rodrigues, Telmo
    Fraile, Susana
    Teodosio, Cristina
    Mayo-Iscar, Agustin
    Aracil, Miguel
    Maria Galmarini, Carlos
    Tirado, Oscar M.
    Mora, Jaume
    de Alava, Enrique
    [J]. ONCOTARGET, 2015, 6 (22) : 18875 - 18890
  • [29] Taking the next step in PARP-inhibitor clinical trials in older women with ovarian cancer - Staging the aging
    Liposits, G.
    Lichtman, S. M.
    [J]. GYNECOLOGIC ONCOLOGY REPORTS, 2021, 35
  • [30] PARP Inhibitor Treatment in Ovarian and Breast Cancer Foreword
    Kummar, Shivaani
    [J]. CURRENT PROBLEMS IN CANCER, 2011, 35 (01) : 6 - 6
12345